ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Project description

A needle-free shot of adrenaline

Anaphylactic shock is an extreme allergic reaction that needs to be treated immediately with a shot of epinephrine (adrenaline) to reverse the symptoms. Many people at risk of anaphylaxis carry an autoinjector – a combined syringe and concealed needle that injects a single dose of medication. This needle-based drug delivery device may soon be replaced by a needle-free alternative. Crossject’s ZENEO device permits needle-free injection of the drug in emergency situations. Under the EU-funded ZENEO project, the company plans to launch ZENEO® Adrenaline on the market by the end of 2021. It estimates a turnover of EUR 136 million and a profit of EUR 124 million by the fifth year of commercialisation.

Fields of science

• medical and health sciences › clinical medicine › allergology › food allergy
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › earth and related environmental sciences › environmental sciences › pollution

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CROSSJECT

Net EU contribution

€ 50 000,00

Address

6 Rue Pauline Kergomard Zac Parc Mazen Sully
21000 Dijon
France

Region

Bourgogne-Franche-Comté › Bourgogne › Côte-d’Or

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 21 429,00